Body and Mind

The first aceclidine-based eye drop to improve near vision in adults with age-related presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration and will be on sale by November.

In a new study from the University of Oregon, scientists turned up the temperature to see which type of passive heat therapy packs the most health punch – hot baths, traditional saunas, or those fancy far-infrared saunas.

Adding to the growing body of research that proves our microbiome is a powerful ally in fighting disease, scientists have found that an easy-to-get nutrient in our food causes our guts to produce powerful insulin-regulating compounds.

A gummy packed with heat-inactivated bacteria could be an easy way to prevent gum disease, with scientists demonstrating that this simple measure alleviates inflammation without upsetting the mouth's microbiome, regardless of oral hygiene habits.

A once-a-day oral GLP-1 pill known as CX11 has met its dosage and efficacy goals in a trial on US patients and will now advance to its first North American Phase 3 trial. It's already cleared this final hurdle in China where it awaits approval.

A landmark study is due to start in the coming months, and if successful it could ultimately revive our immune system in older age and even treat chronic illnesses like autoimmune disease. The Phase 1 trial is aiming to rejuvenate senescent T cells.

University of California, San Francisco (UCSF) scientists have developed a form of neurological pacemaker that adapts in real time to a patient’s walking and could address one of the most disabling and hard-to-treat symptoms of Parkinson’s disease.

Definium Therapeutics has announced the strong Phase 3 results of its single-dosed lysergide drug DT120 in treating adults with major depressive disorder. It met its main goal and all key secondary efficacy endpoints in the first trial of its kind.

In a massive study of 82,826 adults, bright artificial light in the evenings has been tied to age-related eye disease. At the extreme, light exposure was linked to a worrying increase in age-related macular degeneration, cataracts and glaucoma.

People taking fish-oil supplements in an effort to shield their brain from Alzheimer's disease might be better off investing that money in their diet, with a two-year study finding that omega-3 pills offer no protection from cognitive decline.

Scientists have not just found a new way that aging cells drive inflammation, but have also blocked it from happening with an existing FDA-approved drug. This opens the door to an entirely new way to shield the body from age-related health decline.

Weight-loss jabs are the latest craze for shedding a few pounds. But as effective as GLP-1 drugs are, not everyone who uses them will lose a significant amount of weight. Research suggests that between 10% and 30% of patients fit into this group.

A new study suggests the drug’s influence over our brain’s control systems may attenuate behaviors linked to aggression, which, given the widespread use of these pharmaceuticals, could ultimately dampen the rate of violent crime.

In California alone, more than 550 workers have been diagnosed with silicosis caused by this engineered stone used in kitchen construction. This deadly disease is completely preventable – however, once it develops, there's no cure.

We may be on the cusp of understanding whether we can turn back time for our cells to stave off age-related disease, with the first human receiving experimental gene therapy as part of a landmark trial.

A common laxative may do more than aid digestion: it could sharpen memory and attention in people with depression. This existing drug, currently used to treat chronic constipation, has shown promise in tackling these often-overlooked cognitive issues.

We might be on the verge of a critical breakthrough treatment for pattern hair loss, with a novel slow-release oral drug meeting its significant endpoints in a Phase II/III trial of 519 patients. The next results are due later this year.

Colorectal cancer has long been linked to a microbial imbalance in the gut. A new study suggests this dynamic is more complicated than initially thought, with not just bacteria behind it but the viruses living inside them.